Viatris Stock News

Viatris was formed by the merger of Pfizer's Legacy Brands business Upjohn with generic drug developer Mylan.

During the recent session, Viatris Inc. (NASDAQ:VTRS)’s traded shares were 1.9 million, with the beta value of the company hitting 1.31. At the last check today, the stock’s price was $14.93, reflecting an intraday loss of -2.13% or -$0.32. The 52-week high for the VTRS share is $18.68, that puts it down -25.12 from that … Viatris Inc. (NASDAQ: VTRS)’s Stock Is Down -16.53% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »

If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ: VTRS ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. … Full story available on Benzinga.com

John Paulson''s fund, Paulson & Co., opened new positions in Cerner (CERN) (474K shares) and KraneShares CSI China Internet ETF (KWEB) (500K shares) and closed stakes in Pretium…

In the latest trading session, 1.52 million Viatris Inc. (NASDAQ:VTRS) shares changed hands as the company’s beta touched 1.31. With the company’s most recent per share price at $15.53 changing hands around $0.31 or 2.07% at last look, the market valuation stands at $18.41B. VTRS’s current price is a discount, trading about -20.28% off its … Let’s Jump Into The Viatris Inc. (NASDAQ: VTRS) Stock Forecast Read More »

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

While there is ample supply of dividend stocks to be found on Wall Street, finding high-quality ones whose payouts are secure can be a little more tricky.  What's more, following years of big gains i

Dividend Income Summary: Lanny's January 2022 Summary

It's exceptionally cheap and is defying the market downturn so far this year.

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish. Merck & Co., Inc. (NASDAQ: MRK ) issued mixed 2022 guidance and Swiss pharma giant Roche Holding AG (OTC: RHHBY ) warned of slowing growth in 2022. Biogen, Inc. (NASDAQ: BIIB ) shares moved to the downside as they reacted to weak guidance and not-so-promising commentary about sales of the company''s Alzheimer''s drug Aduhelm. On the regulatory front, the Food and Drug Administration approved Viatris Inc.''s (NASDAQ: VTRS ) generic version of AbbVie, Inc.''s (NYSE: ABBV ) dry eye disease drug Restasis. Sanofi (NASDAQ: SNY ) received the nod for its medication Enjaymo, targeting a rare blood disorder known as cold agglutinin disease. LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) shares shed over 50% during the week after the FDA imposed a clinical hold on a Phase 1/2 study of its AAV-delivered genomic editing therapy LB-001 to treat a rate metabolic disorder in children.

It''s shaping up to be a compelling dividend stock.

It's shaping up to be a compelling dividend stock.

Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.

PITTSBURGH, Feb. 4, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will host its investor event the morning of Monday, February 28, 2022, beginning at 8:30 a.m. ET. During the event, Chief Execu